Promoting predictive, preventive and personalized medicine in treatment of cardiovascular diseases

EPMA Journal

Volumn 2, Issue 1, 2011, Pages 1-4

  Iso, Hiroyasu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFORAPHANE; TRIACYLGLYCEROL;

AORTA STENOSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SLEEP APNEA SYNDROME; SMOKING CESSATION PROGRAM; SODIUM RESTRICTION; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

EID: 79955653562     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-011-0075-0     Document Type: Editorial

References (14)

1. Rosolova H, Nussbaumerova B. Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. EPMA J. 2011. doi: 10. 1007/s13167-011-0066-1.
2. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011. doi: 10. 1007/s13167-011-0063-4.
3. Miura K. Epidemiology and prevention of hypertension in Japanese: how could Japan get longevity? EPMA J. 2011. doi: 10. 1007/s13167-011-0069-y.
4. Yatsuya H, Yamagishi Y, Iso H. Adiposity and risk of cardiovascular diseases in Japan: secular trend, individual level associations and causal pathway - implications for the prevention of cardiovascular diseases in societies with rapid economic development. EPMA J. 2011. doi: 10. 1007/s13167-011-0071-4.
5. Kokubo Y. Associations of impaired glucose metabolism and dyslipidemia with cardiovascular diseases: what have we learned from Japanese cohort studies for individualized prevention and treatment? EPMA J. 2011. doi: 10. 1007/s13167-011-0074-1.
6. Iso H. A Japanese health success story: trends in cardiovascular diseases, their risk factors, and the contribution of public health and personalized approaches. EPMA J. 2011. doi: 10. 1007/s13167-011-0067-0.
7. Evans PC. The influence of sulforaphane on vascular health and its relevance to nutritional approaches to prevent cardiovascular disease. EPMA J. 2011. doi: 10. 1007/s13167-011-0064-3.
8. Tuleta I, Pabst S, Juergens UR, Nickenig G, Skowasch D. Obstructive sleep apnoea as a risk factor for atherosclerosis - implication for preventive and personalised treatment. EPMA J. 2011. doi: 10. 1007/s13167-011-0070-5.
9. Tanigawa T. Obstructive sleep apnea: its prevention and screening may contribute to the prevention of hypertension, diabetes and cardiovascular diseases. EPMA J. 2011. doi: 10. 1007/s13167-011-0073-2.
10. Kastrup J. Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome? EPMA J. 2011. doi: 10. 1007/s13167-011-0062-5.
11. Becher UM, Tiyerilli V, Skowasch D, Nickenig G, Werner N. Personalized cardiac regeneration by stem cells - Hype or hope? EPMA J. 2011. doi: 10. 1007/s13167-011-0068-z.
12. Yeghiazaryan K, Skowash D, Bauriedel G, Schild HH, Golubnitschaja O. Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments. EPMA J. 2011. doi: 10. 1007/s13167-011-0072-3.
13. Roberti di Sarsina P, Iseppato I. Why we need integrative medicine. EPMA J. 2011. doi: 10. 1007/s13167-011-0065-2.
14. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998; 97: 596-601.